Ebitda outlook in line with prior year; pleasing doctor partner earnings erosion appears to have been contained. Forecasts don't include any new earnings from acquisition opportunities in play. Panch facility to be up and running in July 2015. At 10 times ebitda $24.5 m 2015, less net debt now around $14m, stock looks cheap, particularly given sector long term outlook.
